By Steven Rogers, MD
The Food and Drug Administration recently approved an extremely promising new treatment for hepatitis C virus. This new medication, sofosbuvir, marketed under the name Sovaldi, is considered a major breakthrough for two reasons: it is much more easily tolerated by patients than previous treatment protocols, and it has proven to be 80-90 percent effective in curing hepatitis C, representing a significant increase over previous approaches to treatment. Sofosbuvir, which works by blocking the ability of the hepatitis C virus to replicate, is a pill that is taken once a day. It received final approval in December 2013 and is available now locally.
